Removing Barriers and Reducing Stigma to Encourage HIV Prevention Amendment Act of 2025

This bill prohibits insurance companies in Washington, D.C., from considering the use of HIV prevention medication (PrEP) when making decisions about disability, life, or long-term care insurance. It directly affects people using PrEP - such as daily pills (Truvada, Descovy) or the injection (Apretude) - who might otherwise face higher premiums, denied coverage, or limited benefits. The key provision amends existing anti-discrimination law to ban insurers from using PrEP use as a factor in underwriting, renewing, or pricing these policies. This aims to remove barriers to PrEP uptake and reduce stigma, supporting D.C.'s goal to lower new HIV diagnoses to under 130 annually by 2030.